Metabotropic glutamate receptors: Targets for therapy of cerebral ischaemia

Expert Opinion on Therapeutic Targets

Volumn 5, Issue 6, 2001, Pages 669-683

  Costantino, Gabriele ^a   Macchiarulo, Antonio ^a   Pellicciari, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Brain ischaemia; Metabotropic glutamate receptors; Neuroprotection

Indexed keywords

EID: 12444302830     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.5.6.669     Document Type: Review

References (99)

1. GOLDSTEIN LB: Medical therapy for acute ischemic stroke. Curr. Atheroscler. Rep. (2001) 3:299-306.
2. DIRNAGL H, IADECOLA C, MOSKOWITZ MA: Pathobiology of ischemic stroke: an integrated view. Trends Neurosci. (1999) 22:391-397.
3. WHITE BC, SULLIVAN JM, DEGRACIA DJ et al.: Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J. Neurol. Sci. (2000) 179(S1-2):1-33.
4. NEUMAR RW: Molecular mechanisms of ischemic neuronal injury. Ann. Emerg. Med. (2000) 36:483-506.
5. CONN PJ, PIN JP: Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. (1997) 37:205-237.
6. BOCKAERT J, PIN JP: Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. (1999) 18:1723-1729.
7. PARMENTIER ML, PIN JP, BOCKAERT J, GRAU Y: Cloning and functional expression of a Drosophila metabotropic glutamate receptor expressed in the embryonic CNS. J. Neurosci. (1996) 16:6687-6694.
8. ALBANI-TORREGROSSA S, ATTUCCI S, MARINOZZI M, PELLICCIARI R, MORONI F, PELLEGRINI-GIAMPIETRO DE: Antagonist pharmacology of metabotropic glutamate receptors coupled to phospholipase D activation in adult rat hippocampus: focus on (2R,1′S,2′R,3′S)-2-(2′-carboxy-3′- phenylcyclopropyl)glycine versus 2,3-dihydroxyphenylglycine. Mol. Pharmacol. (1999) 55:699-707.
9. BOSS VK, CONN PJ: Metabotropic excitatory amino acid receptor activation stimulates phospholipase D in hippocampal slices. J. Neurochem. (1992) 59:2340-2343.
10. BOSS VK, NUTT M, CONN PJ: L-cysteine sulfinic acid as an endogenous agonist of a novel metabotropic receptor coupled to phospholipase D activity. Mol. Pharmacol. (1994) 45:1177-1182.
11. MASU M, TANABE Y, TSUCHIDA K, SHIGEMOTO R, NAKANISHI S: Sequence and expression of a metabotropic glutamate receptor. Nature (1991) 349:760-765.
12. NAKANISHI S: Molecular diversity of glutamate receptors and implications for brain function. Science (1992) 258:597-603.
13. ROMANO C, YANG WL, O'MALLEY K: Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J. Biol. Chem. (1996) 271:28612-28616.
14. O'HARA PJ, SHEPPARD PO, THOGERSEN H et al.: The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. Neuron (1993) 11:41-52.
15. TAKAHASHIK, TSUCHIDA K, TANABE Y, MASU M, NAKANISHIS: Role of the large extracellular domain of metabotropic glutamate receptors in agonist selectivity determination. J. Biol. Chem. (1993) 268:19341-19345.
16. SHIGEMOTO R, ABE T, NOMURA S, NAKANISHI S, HIRANO T: Antibodies inactivating mGluR1 metabotropic glutamate receptor block long-term depression in cultured Purkinje cells. Neuron (1994) 12:1245-1255.
17. OKAMOTO T, SEKIYAMA N, OTSU M et al.: Expression and purification of the extracellular ligand binding region of metabotropic glutamate receptor subtype 1. J. Biol. Chem. (1998) 273:13089-13096.
18. MAO B, PEAR MR, MCCAMMON JA, QUIOCHO FA: Hinge-bending in L-arabinose-binding protein. The "Venus's-flytrap" model. J. Biol. Chwm. (1982) 257:1131-1133.
19. GALVEZ T, PARMENTIER ML, JOLY C et al.: Mutagenesis and modeling of the GABAB receptor extracellular domain support a venus flytrap mechanism for ligand binding. J. Biol. Chem. (1999) 274:13362-13369.
20. COSTANTINO G, PELLICCIARI R: Homology modeling of metabotropic glutamate receptors. (mGluRs) structural motifs affecting binding modes and pharmacological profile of mGluR1 agonists and competitive antagonists. J. Med. Chem. (1996) 39:3998-4006.
21. COSTANTINO G, MACCHIARULO A, PELLICCIARI R: Modeling of amino-terminal domains of group I metabotropic glutamate receptors: structural motifs affecting ligand selectivity. J. Med. Chem. (1999) 42:5390-5401.
22. COSTANTINO G, MACCHIARULO A, PELLICCIARI R: Homology model of the closed, functionally active, form of the amino terminal domain of mGluR1. Bioorg. Med. Chem. (2001) 9:847-852.
23. BESSIS AS, BERTRAND HO, GALVEZ T, DE COLLE C, PIN JP, ACHER F: Three-dimensional model of the extracellular domain of the type 4a metabotropic glutamate receptor: new insights into the activation process. Protein Sci. (2000) 9:2200-2209.
24. JENSEN AA, SHEPPARD PO, O'HARA PJ, KROGSGAARD-LARSEN P, BRAUNER-OSBORNE H: The role of Arg(78) in the metabotropic glutamate receptor mGlu(1) for agonist binding and selectivity. Eur.J. Pharmacol. (2000) 397:247-253.
25. HAMPSON R, HUANG XP, PEKHLETSKI et el.: Probing the ligand-binding domain of the mGluR4 subtype of metabotropic glutamate receptor. J. Biol. Chem. (1999) 274:33488-33495.
26. COSTANTINO G, NATALINI B, PELLICCIARI R, MORONI F, LOMBARDI G: Definition of a pharmacophore for the metabotropic glutamate receptors negatively linked to adenylyl cyclase. Bioorg. Med. Chem. (1993) 1:259-265.
27. COSTANTINO G, MACCHIARULO A, PELLICCIARI R: Pharmacophore models of group I and group II metabotropic glutamate receptor agonists. Analysis of conformational, steric, and topological parameters affecting potency and selectivity. J. Med. Chem. (1999) 42:2816-2827.
28. JULLIAN N, BRABET I, PIN JP, ACHER FC: Agonist selectivity of mGluR1 and mGluR2 metabotropic receptors: a different environment but similar recognition of an extended glutamate conformation. J. Med. Chem. (1999) 42:1546-1555.
29. BESSIS AS, JULLIAN N, COUDERT E, PIN JP, ACHER F: Extended glutamate activates metabotropic receptor types 1, 2 and 4: selective features at mGluR4 binding site. Neuropharmacology (1999) 38:1543-1551.
30. KUNISHIMA N, SHIMADA Y, TSUJI Y et al.: Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature (2000) 407:971-977.
31. ROMANO C, MILLER JK, HYRC K et al.: Covalent and noncovalent interactions mediate metabotropic glutamate receptor mGlu5 dimerization. Mol. Pharmacol. (2001) 59:46-53.
32. DE BLASI A, CONN PJ, PIN J, NICOLETTI F: Molecular determinants of metabotropic glutamate receptor signaling. Trends Pharmacol. Sci. (2001) 22:114-120.
33. ANGO F, PREZEAU L, MULLER T et al.: Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein homer. Nature (2001) 411:962-965.
34. CHOI DW: Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci. (1995) 18:58-60.
35. LUTSEP HL, CLARK WM: Neuroprotection in acute ischaemic stroke. Current status and future potential. Drugs R & D. (1999) 1:3-8.
36. NICOLETTI F, BRUNO V, COPANI A, CASABONA G, KNOPFEL T: Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. (1996) 19:267-271.
37. BRUNO V, BATTAGLIA G, KINGSTON A et al.: Neuroprotective activity of the potent and selective mGlula metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlula and mGlu5 receptors. Neuropharmacology (1999) 38:199-207.
38. FERRAGUTI F, PIETRA C, VALERIO E, CORTIC, CHIAMULERA C, CONQUET F: Evidence against a permissive role of the metabotropic glutamate receptor 1 in acute excitotoxicity, Neuroscience (1997) 79:1-5.
39. PIZZI M, BORONI F, BIANCHETTI KM, MEMO M, SPANO P: Reversal of glutamate excitotoxicity by activation of PKC-associated metabotropic glutamate receptors in cerebellar granule cells relies on NR2C subunit expression. Eur. J. Neurosci. (1999) 11:2489-2496.
40. CHAVIS P, FAGNI L, LANSMAN JB, BOCKAERT J: Functional coupling between ryanodine receptors and L-type calcium channels in neurons. Nature (1996) 382:719-722.
41. STRASSER U, LOBNER D, BEHRENS MM, CANZONIERO LM, CHOI DW: Antagonists for group I mGluRs attenuate excitotoxic neuronal death in cortical cultures. Em. J. Neurosci. (1998) 10:2848-2855.
42. MORISHITA W, KIROV SA, ALGER BE: Evidence for metabotropic glutamate receptor activation in the induction of depolarization-induced suppression of inhibition in hippocampal CA1. J. Neurosci. (1998) 18:4870-4882.
43. BRUNO V, BATTAGLIA G, COPANIA et al.: An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors. Eur. J. Neurosci. (2001) 13:1469-1478.
44. EATON SA, JANE DE, JONES PL et al.: Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-alpha-methyl-4-carboxyphenylglycine. Eur. J. Pharmacol. (1993) 244:195-197.
45. PELLICCIARI R, LUNEIA R, COSTANTINO G et al.: 1-Aminoindan-1,5-dicarboxylic acid: a novel antagonist at phospholipase C-linked metabotropic glutamate receptors. J. Med. Chem. (1995) 38:3717-3719.
46. PELLICCIARI R, RAIMONDO M, MARINOZZI M, NATALINI B, COSTANTINO G, THOMSEN C: (S)-(+)-2-(3′-carboxybicyclo[1.1.1]pentyl)-glycine, a structurally new group I metabotropic glutamate receptor antagonist. J. Med. Chem. (1996) 39:2874-2876.
47. CLARK BR BAKER SR, GOLDSWOTHY J, HARRIS JR, KINGSTON AE: (+)-2-Methyl-4-carboxyphenylglycine (LY367385) selectively antagonises metabotropic glutamate receptors. Bioorg. Med. Chem. Eett. (1997) 7:2777-2780.
48. DOHERTY AJ, PALMER MJ, HENLEY JM, COLLINGRIDGE GL, JANE DE: (RS)-2-chloro-5 hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology (1997) 36:265-267.
49. LITSCHIG S, GASPARINI F, RUEEGG D et al.: CPCCOEr, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. (1999) 55:453-461.
50. GASPARINI F, LINGENHOHL K, STOEHR N et al.: 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology (1999) 38:1493-1503.
51. VARNEY MA, COSFORD ND, JACHEC C et al.: SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J. Pharmacol. Exp. Ther. (1999) 290:170-181.
52. CARROLL FY, STOLLE A, BEART PM et al.: BAY36-7620: a potent non-competitive mGlul receptor antagonist with inverse agonist activity. Mol. Pharmacol. (2001) 59:965-973.
53. PAGANO A, RUEGG D, LITSCHIG S et al.: The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-la-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem. (2000) 275:33750-33758.
54. OTT D, FLOERSHEIM P, INDERBITZIN W et al.: Chiral resolution, pharmacological characterization, and receptor docking of the noncompetitive mGlu1 receptor antagonist (+/-)-2-hydroxyimino-1a, 2-dihydro-1H-7-oxacyclopropa[b]naphthalene-7a-carboxylic acid ethyl ester. J. Med. Chem. (2000) 43:4428-4436.
55. PELLEGRINI-GIAMPIETRO DE, COZZI A, PERUGINELLI F et al.: 1-Aminoindan-1,5-dicarboxylic acid and (S)-(+)-2-(3′-carboxybicyclo[1.1.1] pentyl)-glycine, two mGlu1 receptor-preferring antagonists, reduce neuronal death in vitro and in vivo models of cerebral ischaemia. Eur. J. Neurosci. (1999) 11:3637-3647.
56. KINGSTON AE, O'NEILL MJ, BOND A et al.: Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors. Ann. NY Acad. Sci. (1999) 890:438-449.
57. RAO AM, HATCHER JF, DEMPSEY RJ: Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil. Neurosci. Lett. (2000) 293:1-4
58. BATTAGLIA G, BRUNO V, PISANIA et al.: Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission. Mol. Cell Neurosci. (2001) 17:1071-1083.
59. ALLEN JW, VICINI S, FADEN AI: Exacerbation of neuronal cell death by activation of group I metabotropic glutamate receptors: role of NMDA receptors and arachidonic acid release. Exp. Neurol. (2001) 169:449-460.
60. COZZI A, ATTUCCI S, PERUGINELLI F et al.: Type 2 metabotropic glutamate (mGlu) receptors tonically inhibit transmitter release in rat caudate nucleus: in vivo studies with (2S,1′S,2′S,3′R)-2-(2′-carboxy-3′- phenylcyclopropyl)glycine, a new potent and selective antagonist. Eur. J. Neurosci. (1997) 9:1350-1355.
61. ISHIDA M, SAITOH T, SHIMAMOTO K, OHFUNE Y, SHINOZAKI H: A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the new-born rat isolated spinal cord. Br. J. Pharmacol. (1993) 109:1169-1177.
62. PELLICCIARI R, MARINOZZI M, NATALINI B et al.: Synthesis and pharmacological characterization of all sixteen stereoisomers of 2-(2′-carboxy-3′-phenylcyclopropyl)glycine. Focus on (2S,1′S,2′S,3′R)-2-(2′-carboxy-3′- phenylcyclopropyl)glycine, a novel and selective group II metabotropic glutamate receptors antagonist. J. Med. Chem. (1996) 39: 2259-2269.
63. KOZIKOWSKI AP, STEENSMA D, ARALDI GL et al.: Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist. J. Med. Chem. (1998) 41:1641-1650.
64. MONN JA, VALLI MJ, MASSEY SM et al.: Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem. (1997) 40:528-537.
65. MONN JA, VALLI MJ, MASSEY SM et al.: Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0]hexane- 2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J. Med. Chem. (1999) 42:1027-1040.
66. ORNSTEIN PL, BLEISCH TJ, ARNOLD MB, WRIGHT RA, JOHNSON BG, SCHOEPP DD: 2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylallcyl substitution. J. Med. Chem. (1998) 41:346-357.
67. WROBLEWSKA B, WROBLEWSKI JT, SAAB OH, NEALE JH: N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells. J. Neurochem. (1993) 61:943-948.
68. BOND A, O'NEILL MJ, HICKS CA, MONN JA, LODGE D: Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. Neuroreport (1998) 9:1191-1193.
69. LAM AG, SORIANO MA, MONN JA, SCHOEPP DD, LODGE D, MCCULLOCH J: Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia. Neurosci. Lett. (1998) 254:121-123.
70. BOND A, RAGUMOORTHY N, MONN JA et al.: LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia. Neurosci. Lett. (1999) 273:191-194.
71. KINGSTON AE, O'NEILL MJ, LAM A, BALES KR, MONN JA, SCHOEPP DD: Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795. Eur. J. Pharmacol. (1999) 377:155-165.
72. BRUNO V, BATTAGLIA G, CASABONA G, COPANI A, CACIAGLI F, NICOLETTI F: Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J. Neurosci. (1998) 18:9594-9600.
73. BOND A, JONES NM, HICKS CA et al.: Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. J. Pharmacol. Exp. Ther. (2000) 294:800-809.
74. JACKSON PF, SLUSHER BS: Design of naaladase inhibitors: a novel neuroprotective strategy. Curr. Med. Chem. (2001) 8:949-957.
75. SLUSHER BS, VORNOV JJ, THOMAS AG et al.: Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. (1999) 5:1396-1402.
76. LU XM, TANG Z, LIU W, LIN Q, SLUSHER BS: N-acetylaspartylglutamate protects against transient focal cerebral ischemia in rats. Eur. J. Pharmacol. (2000) 408:233-239.
77. DE COLLE C, BESSIS AS, BOCKAERT J, ACHER F, PIN JP: Pharmacological characterization of the rat metabotropic glutamate receptor type 8a revealed strong similarities and slight differences with the type 4a receptor. Eur. J. Pharmacol. (2000) 394:17-26.
78. GERLAI R, RODER JC, HAMPSON DR: Altered spatial learning and memory in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. Behav. Neurosci. (1998) 112:525-532.
79. LI H, OHISHI H, KINOSHITA A, SHIGEMOTO R, NOMURA S, MIZUNO N: Localization of a metabotropic glutamate receptor, mGluR7, in axon terminals of presumed nociceptive, primary afferent fibers in the superficial layers of the spinal dorsal horn: an electron microscope study in the rat. Neurosci. Lett. (1997) 223:153-156.
80. ACHER FC, TELLIER FJ, AZERAD R, BRABET IN, FAGNI L, PIN JP: Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J. Med. Chem. (1997) 40:3119-3129.
81. AMORI L, COSTANTINO G, MARINOZZI M et al.: Synthesis, molecular modeling and preliminary biological evaluation of 1-amino-3-phosphono-3-cyclopentene-1-carboxylic acid and 1-amino-3-phosphono-2-cyclopentene-1-carboxylic acid, two novel agonists of metabotropic glutamate receptors of group III. Bioorg. Med. Chem. Lett. (2000) 10:1447-1450.
82. TOMS NJ, JANE DE, KEMP MC, BEDINGFIELD JS, ROBERTS PJ: The effects of (RS)-alpha cyclopropyl-4-phosphonophenylglycine ((RS)-CPPG), a potent and selective metabotropic glutamate receptor antagonist. Br. J. Pharmacol. 119: 851-854.
83. GASPARINI F, INDERBITZIN W, FRANCOTTE E et al.: (+)-4-phosphonophenylglycine (PPG) a new group III selective metabotropic glutamate receptor agonist. Bioorg. Med. Chem. Lett. (2000) 10:1241-1244.
84. THOMAS NK, WRIGHT RA, HOWSON PA, KINGSTON AE, SCHOEPP DD, JANE DE: (S)-3.4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology (2001) 40:311-318.
85. BRUNO V, COPANI A, BONANNO L et al.: Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur. J. Pharmacol. (1996) 310:61-66.
86. BRUNO V, BATTAGLIA G, KSIAZEKI et al.: Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J. Neurosci. (2000) 20:6413-6420.
87. SABELHAUS CF, SCHRODER UH, BREDERJ, HENRICH-NOACK P, REYMANN KG: Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R, S)-4-phosphonophenylglycine. Br. J. Pharmacol. (2000) 131:655-658.
88. th: Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat. Neurosci. (2001) 4:417-423.
89. th: Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. J. Neurosci. (2001) 21:3771-3779.
90. FUNDYTUS ME, YASHPAL K, CHABOTJG et al.: Knockdown of spinal metabotropic glutamate receptor 1 (mGluR(1)) alleviates pain and restores opioid efficacy after nerve injury in rats. Br. J. Pharmacol. (2001) 132:354-367.
91. WALKER K, BOWES M, PANESAR M et al.: Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology (2001) 40:1-9.
92. WALKER K, REEVE A, BOWES M et al.: mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology (2001) 40:10-19.
93. BORDI F, UGOLINI A: Involvement of mGluR(5) on acute nociceptive transmission. Brain Res. (2000) 871:223-233.
94. HELTON DR, TIZZANO JP. MONN JA, SCHOEPP DD, KALLMAN MJ: Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. (1998) 284: 651-660.
95. MOGHADDAM B, ADAMS BW: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (1998) 281:1349-1352.
96. rd, HAMPSON DR: Localization of the human mGluR4 gene within an epilepsy susceptibility locus(1). Brain Res. Mol. Brain Res. (2001) 87:109-116.
97. LIE AA, BECKER A, BEHLE K et al.: Up-regulation of the metabotropic glutamate receptor mGluR4 in hippocampal neurons with reduced seizure vulnerability. Ann. Neurol. (2000) 47:26-35.
98. MOLDRICH RX, TALEBI A, BEART PM, CHAPMAN AG, MELDRUM BS: The mGlu(2/3) agonist 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate, is anti-and proconvulsant in DBA/2 mice. Neurosci. Lett. (2001) 299:125-129.
99. YIP PK, MELDRUM BS, RATTRAY M: Elevated levels of group-III metabotropic glutamate receptors in the inferior colliculus of genetically epilepsy-prone rats following intracollicular administration of L-serine-O-phosphate. J. Neurochem. (2001) 78:13-23.